TIGIT is a key inhibitory checkpoint receptor in lymphoma

BACKGROUND: PD-1 checkpoint blockade therapy (CBT) has greatly benefited patients with select solid tumors and lymphomas but has limited efficacy against diffuse large B-cell lymphoma (DLBCL). Because numerous inhibitory checkpoint receptors have been implicated in driving tumor-specific T cell dysf...

Descripción completa

Detalles Bibliográficos
Autores principales: Godfrey, James, Chen, Xiufen, Sunseri, Nicole, Cooper, Alan, Yu, Jovian, Varlamova, Arina, Zarubin, Dmitry, Popov, Yuriy, Jacobson, Connor, Postovalova, Ekaterina, Xiang, Zhongmin, Nomie, Krystle, Bagaev, Aleksander, Venkataraman, Girish, Zha, Yuanyuan, Tumuluru, Sravya, Smith, Sonali M, Kline, Justin P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410806/
https://www.ncbi.nlm.nih.gov/pubmed/37364933
http://dx.doi.org/10.1136/jitc-2022-006582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410806/
https://www.ncbi.nlm.nih.gov/pubmed/37364933
http://dx.doi.org/10.1136/jitc-2022-006582

Ejemplares similares